Abstract
An outbreak of the novel coronavirus 2019-nCoV has led to 7818 cases as of 30th January 2020. Understanding the transmission dynamics of the infection is crucial for evaluating the likely effectiveness of control measures and potential for sustained transmission to occur in new areas. We combined a stochastic transmission model with data on cases 2019-nCoV in Wuhan and exported cases originating in Wuhan to estimate how transmission had varied over time and the likely prevalence of symptomatic cases in the city as of 23rd January 2020. Based on these estimates, we then calculated the probability that newly introduced cases would generate outbreaks in other areas. We estimated that the median reproduction number, R, fluctuated between 1.6–2.9 from mid-December to mid-January 2020. We found that the US, Australia and France had more confirmed cases with travel history to Wuhan than the model predicted, and estimated that there were 29,500 (14,300-85,700) prevalent symptomatic cases in Wuhan on 23rd January 2020, when travel restrictions were introduced. Based on our estimates of R, we calculated that in locations with similar transmission potential as Wuhan, once there are more than three introduced cases, there is a more than 50% chance the infection will establish within that population. Our results show that 2019-nCoV has substantial potential for ongoing human-to-human transmission, and exported cases from Wuhan may have increased prior to travel restrictions being introduced on 23rd January 2020. As more cases arrive in international locations, it is likely many chains of transmission will fail to establish initially, but may still cause new outbreaks eventually.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Wellcome Trust (grants 206250/Z/17/Z and 210758/Z/18/Z) and HDR UK (grant: MR/S003975/1).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data and code are available at: https://github.com/adamkucharski/2020-ncov/stoch_model_V1_paper
